Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H19N4O3S.Na |
Molecular Weight | 370.4035 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[N-]C(=O)NS(=O)(=O)c1c[nH]ccc1=Nc2cccc(C)c2.[Na+]
InChI
InChIKey=BQHGMQPPSXPREC-UHFFFAOYSA-M
InChI=1S/C16H20N4O3S.Na/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13;/h4-11H,1-3H3,(H3,17,18,19,20,21);/q;+1/p-1
Molecular Formula | C16H20N4O3S |
Molecular Weight | 348.4217 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00214Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020136s023lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00214
Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020136s023lbl.pdf
Torasemide is a pyridine-sulfonylurea type loop diuretic mainly used for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Also for the treatment of hypertension alone or in combination with other antihypertensive agents. It is also used at low doses for the management of hypertension. It is marketed under the brand name Demadex. Torasemide inhibits the Na+/K+/2Cl--carrier system (via interference of the chloride binding site) in the lumen of the thick ascending portion of the loop of Henle, resulting in a decrease in reabsorption of sodium and chloride. This results in an increase in the rate of delivery of tubular fluid and electrolytes to the distal sites of hydrogen and potassium ion secretion, while plasma volume contraction increases aldosterone production. The increased delivery and high aldosterone levels promote sodium reabsorption at the distal tubules, and by increasing the delivery of sodium to the distal renal tubule, torasemide indirectly increases potassium excretion via the sodium-potassium exchange mechanism. Torasemide's effects in other segments of the nephron have not been demonstrated. Thus torasemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance. Torasemide's effects as a antihypertensive are due to its diuretic actions. By reducing extracellular and plasma fluid volume, blood pressure is reduced temporarily, and cardiac output also decreases.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095165 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21190426 |
1.0 µM [IC50] | ||
Target ID: CHEMBL2722 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26047574 |
|||
Target ID: GO:0001998 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10406837 |
0.5 µM [IC50] | ||
Target ID: CHEMBL1874 Sources: http://www.drugbank.ca/drugs/DB00214 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Demadex Approved UseDemadex is indicated for the treatment of edema associated with congestive heart failure, renal
disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of
edema associated with chronic renal failure.
Demadex is indicated for the treatment of hypertension alone or in combination with other
antihypertensive agents. Launch Date7.4597761E11 |
|||
Primary | Demadex Approved UseDemadex is indicated for the treatment of edema associated with congestive heart failure, renal
disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of
edema associated with chronic renal failure.
Demadex is indicated for the treatment of hypertension alone or in combination with other
antihypertensive agents. Launch Date7.4597761E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
968.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1549.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1561 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3516 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673928 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
TORSEMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TORSEMIDE unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg 1 times / day multiple, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: Page: p.124 |
unhealthy Health Status: unhealthy Condition: Chronic renal failure Sources: Page: p.124 |
|
800 mg single, intravenous Highest studied dose Dose: 800 mg Route: intravenous Route: single Dose: 800 mg Sources: Page: p.124, 133 |
unhealthy Health Status: unhealthy Condition: Acute renal failure Sources: Page: p.124, 133 |
|
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Disc. AE: Dizziness, Headache... AEs leading to discontinuation/dose reduction: Dizziness (0.1 - 0.5) Sources: Page: p.11Headache (0.1 - 0.5) Nausea (0.1 - 0.5) Weakness (0.1 - 0.5) Vomiting (0.1 - 0.5) Hyperglycemia (0.1 - 0.5) Urination abnormal NOS (0.1 - 0.5) Hyperuricemia (0.1 - 0.5) Hypokalemia (0.1 - 0.5) Excessive thirst (0.1 - 0.5) Hypovolemia (0.1 - 0.5) Impotence (0.1 - 0.5) Esophageal hemorrhage (0.1 - 0.5) Dyspepsia (0.1 - 0.5) |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
Disc. AE: Electrolyte depletion, Electrolyte depletion... Other AEs: Hepatic coma, Tinnitus... AEs leading to discontinuation/dose reduction: Electrolyte depletion Other AEs:Electrolyte depletion Hypokalemia Hepatic coma Sources: Page: p.6Tinnitus Hearing loss |
200 mg 1 times / day multiple, intravenous Studied dose Dose: 200 mg, 1 times / day Route: intravenous Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy n = 44 Health Status: unhealthy Condition: Advanced chronic renal failure Population Size: 44 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dizziness | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Dyspepsia | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Esophageal hemorrhage | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Excessive thirst | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Headache | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Hyperglycemia | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Hyperuricemia | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Hypokalemia | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Hypovolemia | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Impotence | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Nausea | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Urination abnormal NOS | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Vomiting | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Weakness | 0.1 - 0.5 Disc. AE |
200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.11 |
Hearing loss | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
|
Hepatic coma | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
|
Tinnitus | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
|
Electrolyte depletion | Disc. AE | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
Electrolyte depletion | Disc. AE | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
Hypokalemia | Disc. AE | 200 mg 1 times / day multiple, oral (max) Recommended Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease Sources: Page: p.6 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [Inhibition 100 uM] | ||||
yes [Inhibition 100 uM] | ||||
yes [Inhibition 100 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 9.0 |
minor | |||
Page: 9.0 |
minor | |||
Page: 5.0 |
yes | |||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Torasemide. A review of its pharmacological properties and therapeutic potential. | 1991 Jan |
|
Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor. | 2001 May |
|
Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. | 2001 Nov |
|
Torasemide in chronic heart failure: results of the TORIC study. | 2002 Aug |
|
Diuretics in the therapy of hypertension. | 2002 Mar |
|
[Which diuretic in heart failure? For the prognosis, they are not all equal]. | 2002 Mar 28 |
|
[Aggression to the immature kidney]. | 2002 Mar-Apr |
|
Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. | 2003 |
|
[Torasemide (Trifas) in clinical practice--own experience]. | 2003 |
|
Ethacrynic acid and the sulfa-sensitive patient. | 2003 Jan 13 |
|
The effects of the loop diuretics furosemide and torasemide on diuresis in dogs and cats. | 2003 Oct |
|
[Heart failure therapy. Cheap can become expensive]. | 2003 Oct 9 |
|
Calciphylaxis in chronic, non-dialysis-dependent renal disease. | 2003 Sep 29 |
|
CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. | 2004 Dec |
|
Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. | 2004 Dec |
|
Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. | 2004 May |
|
A woman with infectious endocarditis caused by Abiotrophia defectiva. | 2004 Oct |
|
High-Dose Torasemide is Equivalent to High-Dose Furosemide with Hypertonic Saline in the Treatment of Refractory Congestive Heart Failure. | 2005 |
|
[Valsartan in patients with arterial hypertension and type 2 diabetes mellitus. The lapaval study]. | 2005 |
|
Functional characterization of human monocarboxylate transporter 6 (SLC16A5). | 2005 Dec |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. | 2005 Nov |
|
[Torasemide--new generation loop diuretic: clinical pharmacology and therapeutic application]. | 2006 |
|
[A case of severe hyponatremia in a patient suffering from epilepsy and using oxcarbazepine]. | 2006 |
|
[Clinical efficacy and safety of administration of loop diuretic torasemide]. | 2006 |
|
[Diuretic therapy in heart failure]. | 2006 Jan-Feb |
|
Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs. | 2006 Nov |
|
Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure. | 2006 Nov 15 |
|
[Chronotherapy with torasemide in hypertensive patients: increased efficacy and therapeutic coverage with bedtime administration]. | 2006 Nov 18 |
|
Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents. | 2006 Sep |
|
Hospital policies for treatment of acute decompensated heart failure. | 2007 Apr |
|
Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. | 2007 Apr |
|
Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. | 2007 Aug 28 |
|
Torasemide transport by organic anion transporters contributes to hyperuricemia. | 2007 Dec |
|
Vasodilatory action of loop diuretics: a plethysmography study of endothelial function in forearm arteries and dorsal hand veins in hypertensive patients and controls. | 2007 Feb |
|
Effect of torsemide on serum and urine electrolyte levels in dogs with congestive heart failure. | 2007 Jun 16 |
|
Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. | 2007 Mar |
|
Effects of oral administration of furosemide and torsemide in healthy dogs. | 2007 Oct |
|
Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. | 2007 Sep |
|
Secondary pulmonary hypertension: haemodynamic effects of torasemide versus furosemide. | 2008 |
|
Comparative effects of torasemide and furosemide in rats with heart failure. | 2008 Feb 1 |
|
Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy. | 2008 Feb 26 |
|
The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics. | 2008 Jun |
Patents
Sample Use Guides
Congestive Heart Failure
The usual initial dose is 10 mg or 20 mg of once-daily oral Demadex (Torasemide). If the diuretic response is inadequate, the dose should be titrated upward by approximately doubling until the desired diuretic response is obtained. Single doses higher than 200 mg have not been adequately studied.
Chronic Renal Failure
The usual initial dose of Demadex is 20 mg of once-daily oral Demadex.
Hypertension
The usual initial dose is 5 mg once daily. If the 5 mg dose does not provide adequate reduction in blood pressure within 4 to 6 weeks, the dose may be increased to 10 mg once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10406837
Isometric contraction induced by a submaximal concentration of Ang II (10(-7) mol/L) was reduced in a dose-dependent way by torasemide (IC(50)=0.5+/-0.04 umol/L) in cultured vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats..
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 15:29:30 UTC 2021
by
admin
on
Sat Jun 26 15:29:30 UTC 2021
|
Record UNII |
8CJ9QM2V5Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
76969345
Created by
admin on Sat Jun 26 15:29:30 UTC 2021 , Edited by admin on Sat Jun 26 15:29:30 UTC 2021
|
PRIMARY | |||
|
SUB04922MIG
Created by
admin on Sat Jun 26 15:29:30 UTC 2021 , Edited by admin on Sat Jun 26 15:29:30 UTC 2021
|
PRIMARY | |||
|
8CJ9QM2V5Q
Created by
admin on Sat Jun 26 15:29:30 UTC 2021 , Edited by admin on Sat Jun 26 15:29:30 UTC 2021
|
PRIMARY | |||
|
72810-59-4
Created by
admin on Sat Jun 26 15:29:30 UTC 2021 , Edited by admin on Sat Jun 26 15:29:30 UTC 2021
|
NON-SPECIFIC STOICHIOMETRY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |